alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1965 Switching valve (ploss). ( a ) *Identification.* A switching valve (ploss) is a three-way valve located between a stethoscope placed over the heart, a blood pressure cuff, and an earpiece. The valve allows the user to eliminate one sound channel and listen only to a patient's heart or korotkoff (blood pressure) sounds through the other channel.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[47 FR 31142, July 16, 1982, as amended at 54 FR 25048, June 12, 1989; 66 FR 38793, July 25, 2001]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3652 Organophosphate test system. ( a ) *Identification.* An organophosphate test system is a device intended to measure organophosphate metabolites quantitatively in human urine from individuals who have signs and symptoms consistent with cholinesterase poisoning. The data obtained by this device is intended to aid in the confirmation and investigation of organophosphate exposure.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The distribution of these devices is limited to laboratories with experienced personnel who are trained to measure and evaluate organophosphate exposure and guide public health response.
( 2 ) Analytical testing must demonstrate the device has appropriate performance characteristics, including adequate precision and accuracy across the measuring range and near medical decision points.
[82 FR 48415, Oct. 18, 2017]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.9650 Quality control kit for blood banking reagents. ( a ) *Identification.* A quality control kit for blood banking reagents is a device that consists of sera, cells, buffers, and antibodies used to determine the specificity, potency, and reactivity of the cells and reagents used for blood banking.
( b ) *Classification.* Class II (performance standards).
[45 FR 60649, Sept. 12, 1980]
§ 556.410 Metoserpate. ( a ) [Reserved]
( b ) *Tolerances.* The tolerance for metoserpate is: ( 1 ) *Chickens.* Edible tissues (excluding eggs): 0.02 ppm.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See § 520.1422 of this chapter.
From: Robert Anderson/DC/USEPA/US

To: "Frey, Nathan J." <Nathan_J._Frey@omb.eop.gov>

Cc: Karl Simon/DC/USEPA/US@EPA, Nancy Ketcham-Colwill/DC/USEPA/US@EPA, Lori 

Stewart/DC/USEPA/US@EPA, Mary Manners/AA/USEPA/US@EPA, Karen 

Thundiyil/DC/USEPA/US@EPA

Date: 05/19/2011 03:47 PM

Subject: Re: EO 12866 Interagency Comments - E15 misfueling rule

Nathan,

Attached please find EPA's responses to the interagency comments under EO 12866. Please note that 

we've attached both a clean and redline version of the rule in addition to specific responses to the 

summary comments. Also, we have included an expanded write-up on the E10/E0 availability petition in 

addition to an expanded discussion on federalism issues. Please let me know if you have any questions.

Robert K. Anderson

Office of Transportation and Air Quality

U.S. Environmental Protection Agency

Phone: (202) 343.9718

Anderson.Robert@epa.gov

From: Lori Stewart/DC/USEPA/US

To: Nancy Ketcham-Colwill/DC/USEPA/US@EPA, Robert Anderson/DC/USEPA/US@EPA

Cc: Karl Simon/DC/USEPA/US@EPA

Date: 05/10/2011 02:26 PM

Subject: Fw: EO 12866 Interagency Comments - E15 misfueling rule

just in case Karl is tied up, wanted to get these to you

----- Forwarded by Lori Stewart/DC/USEPA/US on 05/10/2011 02:26 PM -----

From: "Frey, Nathan J." <Nathan_J._Frey@omb.eop.gov>

To: Lori Stewart/DC/USEPA/US@EPA

Cc: Karl Simon/DC/USEPA/US@EPA

Date: 05/10/2011 02:23 PM

Subject: EO 12866 Interagency Comments - E15 misfueling rule

Attached please find interagency comments under EO 12866 for the E15 misfueling rule (2060-AQ17). 

Please let me know if you have any questions.[attachment "E15 summary of interagency 

comments.doc" deleted by Robert Anderson/DC/USEPA/US] [attachment "Interagency 

Comments_on_E15_misfueling_rule.docx" deleted by Robert Anderson/DC/USEPA/US]
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     This schedule contains summary financial information extracted from
     first quarter Form 10-QSB and is qualified in its entirety by reference
     to such financial statements.
</LEGEND>                     
<MULTIPLIER>                    1
<CURRENCY>                      U.S. Dollars             
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>               SEP-30-1997         
<PERIOD-START>                  OCT-01-1996   
<PERIOD-END>                    DEC-31-1996   
<EXCHANGE-RATE>                           1   
<CASH>                              211,858   
<SECURITIES>                              0   
<RECEIVABLES>                             0   
<ALLOWANCES>                              0   
<INVENTORY>                               0   
<CURRENT-ASSETS>                    211,858   
<PP&E>                              404,914   
<DEPRECIATION>                      102,380   
<TOTAL-ASSETS>                      514,392   
<CURRENT-LIABILITIES>                49,100   
<BONDS>                                   0   
<PREFERRED-MANDATORY>                     0   
<PREFERRED>                               0   
<COMMON>                            122,146   
<OTHER-SE>                                0   
<TOTAL-LIABILITY-AND-EQUITY>        514,392   
<SALES>                                   0   
<TOTAL-REVENUES>                     28,200   
<CGS>                                     0   
<TOTAL-COSTS>                        12,066   
<OTHER-EXPENSES>                          0   
<LOSS-PROVISION>                          0   
<INTEREST-EXPENSE>                    3,517   
<INCOME-PRETAX>                      16,134   
<INCOME-TAX>                              0   
<INCOME-CONTINUING>                  16,134   
<DISCONTINUED>                        2,587   
<EXTRAORDINARY>                           0   
<CHANGES>                                 0   
<NET-INCOME>                         13,547   
<EPS-PRIMARY>                           .00   
<EPS-DILUTED>                           .00   
        

</TABLE>
EX-10.2



 EXHIBIT 10.2 

BELMONT SAVINGS BANK 

SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN 

APPENDIX A-2 

Except as otherwise defined in this Appendix, the terms used herein shall have the meaning(s) ascribed to them in the Belmont Savings Bank
Supplemental Executive Retirement Plan (“Plan”), to which this Appendix, as amended from time to time, is appended and into which this Appendix is incorporated by reference. 

Participant’s Benefit Percentage: 20% of Participant’s Final Average Compensation (as defined in the Plan), multiplied by the
Participant’s Vested Percentage, as set forth herein: 
  

									
	Participant Name	  	Date of Hire	 	  	Years of Service	  	Vested Percentage
	 Hal Tovin
	  	 	July 12, 2010	 	  	5-9	  	50%
		  				  	10 or more	  	100%

 Notwithstanding the foregoing, if prior to the completion of ten (10) Years of Service, the Participant either is
terminated by the Bank without Cause or resigns for Good Reason, the Participant’s “Benefit Percentage” shall be multiplied by the following: 
  

			
	Years of Service	  	Vested Percentage
	 5
	  	60%
	 6
	  	70%
	 7
	  	80%
	 8
	  	90%
	 9
	  	100%


  
 A-2
Exhibit 1 

 
Exhibit 1
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5520 Immunoglobulin G (Fab fragment specific) immunological test system. ( a ) *Identification.* An immunoglobulin G (Fab fragment specific) immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the Fab antigen-binding fragment resulting from breakdown of immunoglobulin G antibodies in urine, serum, and other body fluids. Measurement of Fab fragments of immunoglobulin G aids in the diagnosis of lymphoproliferative disorders, such as multiple myeloma (tumor of bone marrow cells), Waldenstrom's macroglobulinemia (increased immunoglobulin production by the spleen and bone marrow cells), and lymphoma (tumor of the lymphoid tissues).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 61 FR 1119, Jan. 16, 1996; 66 FR 38793, July 25, 2001]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.5260 Automated cell-locating device. ( a ) *Identification.* An automated cell-locating device is a device used to locate blood cells on a peripheral blood smear, allowing the operator to identify and classify each cell according to type. (Peripheral blood is blood circulating in one of the body's extremities, such as the arm.)
( b ) *Classification.* Class II (performance standards).
[45 FR 60597, Sept. 12, 1980]
# C_2014361EN.01000901.xml

| 13.10.2014 | EN | Official Journal of the European Union | C 361/9 |
| --- | --- | --- | --- |

13.10.2014

EN

Official Journal of the European Union

C 361/9

---

Order of the General Court of 1 August 2014 — Energy Brands v OHIM — Smart Wines (SMARTWATER)

(Case T-81/14) (1)

1

((Community trade mark - Opposition proceedings - Withdrawal of the opposition - No need to adjudicate))

2014/C 361/10

Language of the case: English

Parties

Parties

Applicant: Energy Brands, Inc. (Atlanta, United States) (represented by: D. Stone and R. Allos, Solicitors)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: P. Geroulakos, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court: Smart Wines GmbH (Cologne, Germany) (represented by: I. Schwarz, lawyer)

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court:

Re:

Re:

Action brought against the decision of the Second Board of Appeal of OHIM of 19 November 2013 (case R 903/2013-2), relating to opposition proceedings between Energy Brands, Inc. and Smart Wines GmbH.

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to adjudicate on the action. |
| --- | --- |

1.

There is no longer any need to adjudicate on the action.

| 2. | The applicant, the defendant and the intervener shall each bear their own costs. |
| --- | --- |

2.

The applicant, the defendant and the intervener shall each bear their own costs.

---

(1)  OJ C 135, 5.5.2014.

1

---
#### § 2.110 Definition of ammonia under Federal Caustic Poison Act.

For the purpose of determining whether an article containing ammonia is subject to the Federal Caustic Poison Act, the ammonia content is to be calculated as NH3.
# C_2016016EN.01003501.xml

| 18.1.2016 | EN | Official Journal of the European Union | C 16/35 |
| --- | --- | --- | --- |

18.1.2016

EN

Official Journal of the European Union

C 16/35

---

Judgment of the General Court of 19 November 2015 — North Drilling v Council

(Case T-539/14) (1)

1

((Common foreign and security policy - Restrictive measures against Iran with the aim of preventing nuclear proliferation - Freezing of funds - Error of assessment - Temporal adjustment of the effects of an annulment))

(2016/C 016/43)

Language of the case: Spanish

Parties

Parties

Applicant: North Drilling Co. (Tehran, Iran) (represented by: J. Viñals Camallonga, L. Barriola Urruticoechea and J. Iriarte Ángel, lawyers)

Applicant:

Defendant: Council of the European Union (represented by: A. de Elera-San Miguel Hurtado and M. Bishop, acting as Agents)

Defendant:

Re:

Re:

Application for annulment of Council Decision 2014/222/CFSP of 16 April 2014 amending Decision 2010/413/CFSP concerning restrictive measures against Iran (OJ 2014 L 119, p. 65), and Council Implementing Regulation (EU) No 397/14 of 16 April 2014 implementing Regulation (EU) No 267/2012 concerning restrictive measures against Iran (OJ 2014 L 119, p. 1), in so far as those acts concern the applicant.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Annuls Article 1 of Council Decision 2014/222/CFSP of 16 April 2014 amending Decision 2010/413/CFSP concerning restrictive measures against Iran, and Article 1 of Council Implementing Regulation (EU) No 397/14 of 16 April 2014 implementing Regulation (EU) No 267/2012 concerning restrictive measures against Iran (OJ 2014 L 119, p. 1), in so far as they concern North Drilling Co.; |
| --- | --- |

1.

Annuls Article 1 of Council Decision 2014/222/CFSP of 16 April 2014 amending Decision 2010/413/CFSP concerning restrictive measures against Iran, and Article 1 of Council Implementing Regulation (EU) No 397/14 of 16 April 2014 implementing Regulation (EU) No 267/2012 concerning restrictive measures against Iran (OJ 2014 L 119, p. 1), in so far as they concern North Drilling Co.;

| 2. | Orders the effects of Article 1 of Decision 2014/222 and Article 1 of Implementing Regulation No 397/2014 to be maintained in respect of North Drilling until the date of expiry of the period for bringing an appeal stated in the first paragraph of Article 56 of the Statute of the Court of Justice of the European Union or, if an appeal has been brought within that period, until the dismissal of that appeal; |
| --- | --- |

2.

Orders the effects of Article 1 of Decision 2014/222 and Article 1 of Implementing Regulation No 397/2014 to be maintained in respect of North Drilling until the date of expiry of the period for bringing an appeal stated in the first paragraph of Article 56 of the Statute of the Court of Justice of the European Union or, if an appeal has been brought within that period, until the dismissal of that appeal;

| 3. | Orders the Council of the European Union to pay the costs. |
| --- | --- |

3.

Orders the Council of the European Union to pay the costs.

---

(1)  OJ C 303, 8.9.2014.

1

---
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1590 Porphobilinogen test system. ( a ) *Identification.* A porphobilinogen test system is a device intended to measure porphobilinogen (one of the derivatives of hemoglobin which can make the urine a red color) in urine. Measurements obtained by this device are used in the diagnosis and treatment of porphyrias (primarily inherited diseases associated with disturbed porphyrine metabolism), lead poisoning, and other diseases characterized by alterations in the heme pathway.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2307, Jan. 14, 2000]
§ 74.1707a Ext. D&C Yellow No. 7. ( a ) *Identity.* ( 1 ) The color additive Ext. D&C Yellow No. 7 is principally the disodium salt of 8-hydroxy-5,7-di-nitro-2-naphthalenesulfonic acid.
( 2 ) Color additive mixtures for drug use made with Ext. D&C Yellow No. 7 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* Ext. D&C Yellow No. 7 shall conform to the following specifications and shall be free from impurities, other than those named, to the extent that such other impurities may be avoided by good manufacturing practice: Sum of volatile matter (at 135 °C) and chlorides and sulfates (calculated as sodium salts), not more than 15 percent. Water-insoluble matter, not more than 0.2 percent. 1-Naphthol, not more than 0.2 percent. 2,4-Dinitro-1-naphthol, not more than 0.03 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 85 percent.
( c ) *Uses and restrictions.* Ext. D&C Yellow No. 7 may be safely used in externally applied drugs in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of Ext. D&C Yellow No. 7 shall be certified in accordance with regulations in part 80 of this chapter.
§ 520.2184 Sulfachloropyrazine. ( a ) *Specifications.* Each gram of powder contains 476 milligrams of sodium sulfachloropyrazine monohydrate.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerance.* See § 556.625 of this chapter.
( d ) *Conditions of use in chickens.* It is used in the drinking water of broilers, breeder flocks, and replacement chickens as follows: ( 1 ) *Amount.* Administer in drinking water as 0.03 percent solution for 3 days.
( 2 ) *Indications for use.* For the treatment of coccidiosis.
( 3 ) *Limitations.* Withdraw 4 days prior to slaughter. Do not use in chickens producing eggs for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28829, May 20, 2014, as amended at 81 FR 94990, Dec. 27, 2016]
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Wage Chronology: North Atlantic Longshoremen, 1934-71

              																	United States. Bureau of Labor Statistics. 						*Wage Chronology: North Atlantic Longshoremen, 1934-71 : Bulletin of the United States Bureau of Labor Statistics, No. 1736*,												Washington, D.C: 								For sale by the Supt. of Docs., U.S. Govt. Print. Off., 										1972,									https://fraser.stlouisfed.org/title/4897,			accessed on September 26, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
<PAGE>   1



                                                                   EXHIBIT 99.1

                    LXR ANNOUNCES SUSPENSION OF SEC REPORTING

Contact:     LXR Biotechnology Inc.
             510.758.4396

        Richmond, California - December 28, 1999 - LXR Biotechnology Inc. (OTC
BB: LXRI) announced today that it intends to suspend the registration of its
stock with the Securities and Exchange Commission by the end of calendar year
1999. The suspension, which will enable cost savings to the company, will take
effect automatically upon the filing of required forms with the SEC, subject to
SEC review. The filing will be based on the decrease in the number of LXR
stockholders below the level requiring continued registration.

        LXR's shares are currently traded on the Nasdaq OTC Bulletin Board under
the symbol LXRI. As a result of the suspension of its SEC reporting obligations,
LXR will no longer be eligible to be traded on the OTC Bulletin Board. LXR
shares may continue to trade on the so-called "pink sheets."

        In addition, LXR announced that it has agreed with US Bancorp Piper
Jaffray to suspend that firm's search for a purchaser of the company or its
technology. LXR will continue to evaluate the feasibility of selling either the
company or its remaining assets. The company has effectively discontinued
operations while it undertakes this evaluation.

LXR Biotechnology Inc. is a biopharmaceutical company with intellectual property
and research technology for the development of innovative therapeutics to treat
diseases through the control of apoptosis or gene-directed cell death. LXR's
compounds include HK-Cardiosol(TM), CP-Cardiosol(TM) and Elirex(TM).

        SOURCE: LXR Biotechnology Inc.
<PAGE>

                                                                    EXHIBIT 23.1

                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

         As independent public accountants, we hereby consent to the
incorporation of our reports dated February 10, 2000, included on pages F-2
and S-1 of the 1999 Annual Report to Shareholders on Form 10-K of UroCor,
Inc., into the previously filed Registration Statements on Form S-8 (File No.
333-16075, 333-58013, 333-58015 and 333-58017) of UroCor, Inc.



                                                             ARTHUR ANDERSEN LLP

Oklahoma City, Oklahoma,
February 10, 2000
```

[115th Congress Public Law 316]
[From the U.S. Government Publishing Office]

[[Page 132 STAT. 4433]]

Public Law 115-316
115th Congress

                                 An Act

 
To designate the facility of the United States Postal Service located at 
   3s101 Rockwell Street in Warrenville, Illinois, as the ``Corporal 
    Jeffrey Allen Williams Post Office Building''. <<NOTE: Dec. 14, 
                         2018 -  [H.R. 4407]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,
SECTION 1. CORPORAL JEFFREY ALLEN WILLIAMS POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 3s101 Rockwell Street in Warrenville, Illinois, shall be 
known and designated as the ``Corporal Jeffrey Allen Williams Post 
Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Corporal 
Jeffrey Allen Williams Post Office Building''.

    Approved December 14, 2018.

LEGISLATIVE HISTORY--H.R. 4407:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 164 (2018):
            July 16, considered and passed House.
            Nov. 15, considered and passed Senate, amended.
            Dec. 11, House concurred in Senate amendments.

                                  <all>
```